Connect with us

Headlines

Ocular Therapeutix Begins $75M Public Stock Offering

The company makes Dextenza for treatment of inflammation and pain following ophthalmic surgery.

mm

Published

on

BEDFORD, MA — Ocular Therapeutix Inc., a biopharmaceutical company focused on conditions of the eye, has begun a $75 million public stock offering.

The company’s products include Dextenza, an FDA-approved corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery.

The company (Nasdaq: OCUL) is expected to grant the underwriters of the offering a 30-day option to purchase up to an additional $11.25 million of its common stock. All of the shares in the offering are to be sold by the company.

The release notes: “The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.”

Jefferies LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering.

In November 2019, Ocular Therapeutix announced an operational restructuring plan.

Advertisement

The plan was expected to result in about $11 million in annualized savings through personnel reductions and $14 million in “one-time program deferrals,” according to a press release at the time. The company did not say how many jobs would be cut.

With the restructuring, the company is looking to focus resources on Dextenza.

 

Advertisement

SPONSORED VIDEO

SPONSORED BY TOPCON HEALTHCARE

Perform Refraction from Anywhere with RDx

Now more than ever, you need to grow your practice beyond your physical location and deliver quality eye exams from virtually anywhere. Topcon RDx® is an innovative ocular telehealth platform that allows you to connect to your office remotely and conduct comprehensive eye exams, without sacrificing the quality care you provide.

Promoted Headlines

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular